Department of Medicine, Royal Free Hospital, London, UK
Department of Otorhinolaryngology, Wexham Park Hospital, Slough, UK.
BMJ Case Rep. 2023 Jan 30;16(1):e253302. doi: 10.1136/bcr-2022-253302.
We present the case of a teenaged boy who attended our Ear, Nose and Throat Emergency clinic with a left-sided lower motor neuron (LMN) facial nerve paralysis associated with sensory loss in the distribution of the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve. This happened 3 days following a first dose of the Pfizer-BioNTech BNT162b2 vaccine. He had a House-Brackmann grade V facial palsy, with marked inability to close the left eye. He was treated with a 10-day course of oral steroids and referred to ophthalmology for eye care. He had an MRI scan of the head, which revealed no space occupying lesions or other abnormalities. Over the 6-week period of follow-up, the patient's V1 and V2 sensation gradually resolved, along with improvement of his LMN facial nerve palsy to House-Brackmann grade 3. Despite the potential temporal relationship, it is not possible to establish a causal relationship between the patient's symptoms and the Pfizer-BioNTech BNT162b2 vaccine, thus further research is required.
我们报告了 1 例青少年男性患者,他因左侧下运动神经元(LMN)面神经麻痹就诊于耳鼻喉科急诊,同时伴有三叉神经眼支(V1)和上颌支(V2)分布区的感觉丧失。该患者在接种辉瑞-生物科技公司的 BNT162b2 疫苗第一针后 3 天出现上述症状。他的面神经麻痹程度为 House-Brackmann 分级 V 级,左眼完全无法闭合。他接受了 10 天的口服皮质类固醇治疗,并被转至眼科进行眼部护理。头部 MRI 扫描未见占位性病变或其他异常。在 6 周的随访期间,患者的 V1 和 V2 感觉逐渐恢复,同时他的 LMN 面神经麻痹也改善至 House-Brackmann 分级 3 级。尽管存在潜在的时间关系,但无法确定患者的症状与辉瑞-生物科技公司的 BNT162b2 疫苗之间存在因果关系,因此需要进一步研究。